Recently Funded Research
Prof. Richard Costello (centre)
|
Dr. Keith Murphy and his team
|
Prof. Kay Ohlendieck (centre)
|
One of MDI’s aims is to fund and support research relating to neuromuscular conditions. Over the last ten years, MDI has directly provided over €300,000 of research funding.
Research that MDI has funded over the last ten years includes:
2012
Dr. Aisling Ryan, Cork University Hospital and Prof. Orla Hardiman, Beaumont Hospital
Funding to undertake a population-based survey of adult neuromuscular disease in the Republic of Ireland, with particular emphasis on the identification of conditions for which therapeutic options are now available. A secondary aim is to generate specific care programmes for patients with adult onset neuromuscular conditions in the context of two national referral clinics in Dublin and Cork.
2011
Prof. Richard Costello, Beaumont Hospital
Funding to purchase ten oximeters. These devices can be worn overnight at home and give a simple measure of respiratory function, reducing the need for adults with neuromuscular conditions who require assessment of respiratory function to have an overnight stay in hospital for a sleep study.
Dr. Keith Murphy, University College Dublin
Novel Treatment for Charcot-Marie-Tooth Disease
Prof. Kay Ohlendieck, NUI Maynooth
Establishment of a protein biomarker signature for x-linked muscular dystrophy: Identification of novel integral muscle proteins by mass spectrometry-based proteomics
2010
Dr. Matthew Wood, University of Oxford
Enhanced Systemic Delivery of Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy:
Additional funding for one year to improve the delivery of antisense oligonucleotides to target all muscles including the heart.
2009
Dr. Bryan Lynch, CRC Dublin
Funding to employ a Clinical Research Fellow performing audits of care management and researching bone density in boys with Duchenne muscular dystrophy
2008
Dr. Matthew Wood, University of Oxford
Enhanced Systemic Delivery of Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy
Dr. Deniz Yilmazer-Hanke, University College Cork
Contribution of the Inflammatory Reaction in the Muscle in Duchenne Muscular Dystrophy to Depression: Development of New Treatment Strategies
2006
MDEX Consortium, UK
Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: A UK Consortium for Preclinical Optimisation and a Phase I/II Clinical Trial Using Antisense Oligonucleotides
Prof. Kay Ohlendieck, NUI Maynooth
Identification of Novel Biomarkers in Dystrophic Heart and Muscle Fibres Using Comparative Proteomics
2002
Prof. Kay Ohlendieck, NUI Maynooth
Identification of Novel Therapeutic Targets in Dystrophic Muscle Fibres
Research that MDI has funded over the last ten years includes:
2012
Dr. Aisling Ryan, Cork University Hospital and Prof. Orla Hardiman, Beaumont Hospital
Funding to undertake a population-based survey of adult neuromuscular disease in the Republic of Ireland, with particular emphasis on the identification of conditions for which therapeutic options are now available. A secondary aim is to generate specific care programmes for patients with adult onset neuromuscular conditions in the context of two national referral clinics in Dublin and Cork.
2011
Prof. Richard Costello, Beaumont Hospital
Funding to purchase ten oximeters. These devices can be worn overnight at home and give a simple measure of respiratory function, reducing the need for adults with neuromuscular conditions who require assessment of respiratory function to have an overnight stay in hospital for a sleep study.
Dr. Keith Murphy, University College Dublin
Novel Treatment for Charcot-Marie-Tooth Disease
Prof. Kay Ohlendieck, NUI Maynooth
Establishment of a protein biomarker signature for x-linked muscular dystrophy: Identification of novel integral muscle proteins by mass spectrometry-based proteomics
2010
Dr. Matthew Wood, University of Oxford
Enhanced Systemic Delivery of Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy:
Additional funding for one year to improve the delivery of antisense oligonucleotides to target all muscles including the heart.
2009
Dr. Bryan Lynch, CRC Dublin
Funding to employ a Clinical Research Fellow performing audits of care management and researching bone density in boys with Duchenne muscular dystrophy
2008
Dr. Matthew Wood, University of Oxford
Enhanced Systemic Delivery of Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy
Dr. Deniz Yilmazer-Hanke, University College Cork
Contribution of the Inflammatory Reaction in the Muscle in Duchenne Muscular Dystrophy to Depression: Development of New Treatment Strategies
2006
MDEX Consortium, UK
Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: A UK Consortium for Preclinical Optimisation and a Phase I/II Clinical Trial Using Antisense Oligonucleotides
Prof. Kay Ohlendieck, NUI Maynooth
Identification of Novel Biomarkers in Dystrophic Heart and Muscle Fibres Using Comparative Proteomics
2002
Prof. Kay Ohlendieck, NUI Maynooth
Identification of Novel Therapeutic Targets in Dystrophic Muscle Fibres
